GET DAILY SIGNALSWhy Is Twist Bioscience (TWST) Stock Up +4.51% Today?
Key Takeaways
- TWST climbed 4.51% on the session, closing at $149.13, up $6.43 from the prior close of $142.70.
- The rebound followed a sharp multi-day pullback and renewed selling by ARK Invest, with buyers stepping in on the company's AI-driven drug discovery positioning.
- Wall Street has been re-rating the stock, with Barclays, Canaccord Genuity, TD Cowen, and Guggenheim all raising price targets in recent weeks.
- The life science tools sector has enjoyed one of its strongest quarters in two decades, lifting peers and exchange-traded funds tracking the group.
- Traders are now watching the November 13 earnings report, ongoing AI-partnership news flow, and whether the stock can hold above key technical levels.
Opening Summary
Twist Bioscience Corporation (TWST), a South San Francisco-based manufacturer of synthetic DNA built on a proprietary silicon-chip platform, saw its shares surge on Wednesday. The stock rose 4.51% to close at $149.13, up $6.43 from the previous session's close of $142.70. The gain marked a sharp intraday turnaround: shares had opened lower and traded down in pre-market activity before buyers drove a powerful recovery. Market participants pointed to renewed enthusiasm for the company's role as a critical supplier of synthetic DNA to the fast-growing artificial-intelligence-driven drug discovery industry as the primary catalyst behind the advance.
AI Drug Discovery Demand Takes Center Stage
The most immediate driver of the move was the market's growing conviction that TWST sits at a crucial "bottleneck" in the emerging AI-enabled biology workflow. As machine-learning models generate vast numbers of novel protein and DNA sequences, those digital designs must be physically synthesized and tested in the lab — a step that relies heavily on Twist's high-throughput DNA synthesis and protein expression capabilities. The company's prominent role at the BioJapan 2026 conference, where it was spotlighted as a key supplier to AI-driven drug discovery, reinforced this narrative and helped reignite buying interest.
This positioning builds on earlier momentum from Twist's designation as an independent evaluator in an AI-driven protein design campaign, a development that placed the company directly in the center of one of the year's most-watched biotechnology themes. Management has framed AI-driven discovery as a durable, multi-year growth engine, projecting that AI-related order volumes could roughly double again in the coming fiscal year.
Wall Street Re-Rating and Analyst Momentum
The price rally was also supported by a wave of bullish analyst activity. Barclays raised its price target to $215, Canaccord Genuity lifted its objective to $205, TD Cowen increased its target to $190, and Guggenheim moved to $212 — all in recent weeks — as firms re-rated TWST from a niche tools provider into a foundational infrastructure play for computational biology. Analysts have pointed to increasing utilization of the platform and a potential AI tailwind across life science tools as reasons for higher revenue estimates and margin-expansion assumptions.
A Rebound After a Sharp Pullback
Wednesday's advance also reflected a technical and sentiment rebound. Shares had retreated sharply from recent highs amid a pullback in the broader AI-biotech complex and reported selling by ARK Invest, which offloaded more than $18 million of stock. With the stock trading well above its 200-day moving average but below its recent peak, dip buyers re-entered, viewing the prior session's decline as a buying opportunity rather than a fundamental deterioration. The stock's elevated beta of roughly 2.19 amplified the intraday swing in both directions.
Market Context and Trading Activity
The move occurred against a supportive backdrop for the life science tools and diagnostics sector, which analysts have described as experiencing one of its strongest quarters in two decades, driven by recovering biotech funding, AI demand, and improved commercial execution. The rally came on relatively light volume, with turnover running below the stock's recent average — a dynamic some traders flagged as a caution even as price action remained decisively positive. Technically, the stock reclaimed territory above several near-term moving averages, though it remained below its 52-week high set earlier in October.
What Comes Next for TWST
Looking ahead, the next major catalyst for TWST is its earnings report, estimated for November 13, when investors will assess whether revenue growth and AI-related order momentum can justify the stock's elevated valuation. The company remains loss-making on a GAAP basis, with a price-to-sales ratio well above most biotech peers, leaving it sensitive to any disappointment on growth or guidance. Additional AI-partnership announcements, changes in sector sentiment, and broader market appetite for high-beta growth names will also influence the stock's direction. Risks include intensifying competition in DNA synthesis, pricing pressure, and continued dependence on financing given persistent cash burn.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated strong performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols. Because only the strongest performers are featured at any given time, this section offers a useful starting point for traders seeking data-driven, systematic approaches to the market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TWST sees MACD Histogram just turned negative
TWST saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 40 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for TWST moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 37 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 80%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 66 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
TWST moved below its 50-day moving average on October 15, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +6.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 190 of 228 cases where TWST Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.182) is normal, around the industry mean (2.988). TWST has a moderately low P/E Ratio (-66.874) as compared to the industry average of (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 84 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology
Advertisement